Fibrosis clinical trials at UCSF
21 in progress, 13 open to eligible people
4D-710 in Adult Patients With Cystic Fibrosis
open to eligible people ages 18 years and up
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
San Francisco, California and other locations
Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
open to eligible people ages 18-85
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease …
Fresno, California and other locations
BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
open to eligible people ages 40 years and up
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
San Francisco, California and other locations
BMS-986278 in Participants With Progressive Pulmonary Fibrosis
open to eligible people ages 21 years and up
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
San Francisco, California and other locations
CirrhosisRx CDS System
open to eligible people ages 18 years and up
The aim of the study is to compare the effect of CirrhosisRx, a novel clinical decision support (CDS) system for inpatient cirrhosis care, versus "usual care" on adherence to national quality measures and clinical outcomes for hospitalized patients…
San Francisco, California
DWN12088 in Patients With IPF
open to eligible people ages 40 years and up
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
San Francisco, California and other locations
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
open to eligible people ages 18-75
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
San Francisco, California and other locations
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
open to eligible people ages 40 years and up
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
San Francisco, California and other locations
Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
open to eligible people ages 40-85
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment…
San Francisco, California and other locations
Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
open to eligible people ages 18-75
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body…
San Francisco, California and other locations
Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
open to eligible people ages 18-75
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can…
San Francisco, California and other locations
Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
open to eligible people ages 12 years and up
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not …
San Francisco, California and other locations
Liver Cirrhosis Network Cohort Study
open to eligible people ages 18 years and up
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an…
San Francisco, California and other locations
Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Sorry, in progress, not accepting new patients
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Fresno, California and other locations
Long-term Safety and Efficacy of VX-121 Combination Therapy
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
San Francisco, California and other locations
Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis
Sorry, in progress, not accepting new patients
This phase III, randomized, double-blind, placebo-controlled, multi-center study seeks to test whether simvastatin, a statin usually used to lower cholesterol to prevent heart problems and strokes, can lower the risk of hepatic decompensation…
San Francisco, California and other locations
Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Sorry, in progress, not accepting new patients
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
San Francisco, California and other locations
Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sorry, in progress, not accepting new patients
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
San Francisco, California and other locations
Phage for CF Subjects With Pseudomonas Lung Infection
Sorry, not yet accepting patients
The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in…
San Francisco, California and other locations
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
Sorry, not accepting new patients
The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have…
San Francisco, California and other locations
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
Sorry, accepting new patients by invitation only
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as retrospective standard of care…
San Francisco, California and other locations
Our lead scientists for Fibrosis research studies include Jonathan Singer, MD Harold Chapman, MD Jin Ge Jeffrey Golden, MD.
Last updated: